Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04895709 · ClinicalTrials.gov registry record · Phase 1
A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors
A Phase 1 study of Non-Small Cell Lung Cancer and Melanoma, sponsored by Bristol-Myers Squibb.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 949
- Enrollment target
- 20
- Study locations
NCT04895709: Recruiting Phase 1 study of Non-Small Cell Lung Cancer and Melanoma, sponsored by Bristol-Myers Squibb.
NCT04895709 is a Phase 1 study of Non-Small Cell Lung Cancer and Melanoma that is actively recruiting participants, run by Bristol-Myers Squibb. The registered enrollment target is 949 participants, above the 650-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (46% higher). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04895709, a Phase 1 study of Non-Small Cell Lung Cancer and Melanoma, is actively recruiting participants, sponsored by Bristol-Myers Squibb.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 949 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to assess the safety, tolerability, and recommended dose(s) of BMS-986340 as monotherapy and in combination with nivolumab or docetaxel in participants with advanced solid tumors. This study is a first-in-human (FIH) study of BMS-986340 in participants with advanced solid tumors.
Conditions Studied
Interventions
- DRUG Docetaxel
- DRUG BMS-986340
- DRUG BMS-936558-01
Study Locations (20)
California
- Community Cancer Institute - Clovis
- USC/Norris Comprehensive Cancer Center - Los Angeles
- Hoag Memorial Hospital Presbyterian - Newport Beach
New York
- Local Institution - 0006 - New York
- Local Institution - 0002 - New York
Tennessee
- Local Institution - 0063 - Nashville
- Vanderbilt University Medical Center - Nashville
New South Wales
- Blacktown Hospital - Blacktown
- Liverpool Hospital - Liverpool
Victoria
- Cabrini Hospital - Malvern - Malvern
- St Vincent's Hospital - Melbourne
Iowa
- Local Institution - 0062 - Iowa City
New Jersey
- John Theurer Cancer Center - Hackensack
Oregon
- Local Institution - 0001 - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 949 participants |
| Start Date | 2021-05-27 |
| Est. Completion | 2028-07-07 |
| Phase | Phase 1 |
What NCT04895709 shows while recruiting
NCT04895709 is an interventional study that assigns participants to a tested intervention. The registered 949 participants enrollment target is mid-sized for trials with a published cap, above the 650-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (46% higher).
The record links to 10 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 3 interventions - of which Docetaxel is the first listed.
NCT04895709 names 20 study sites across 14 states, led by California, New York, Tennessee.
Frequently Asked Questions
What is clinical trial NCT04895709 about?
NCT04895709 is a clinical study titled "A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors". The purpose of this study is to assess the safety, tolerability, and recommended dose(s) of BMS-986340 as monotherapy and in combination with nivolumab or docetaxel in participants with advanced solid tumors. This study is a first-in-human (FIH) study of BMS-986340 in participants with advanced soli...
What is the current status of trial NCT04895709?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 949 participants. The study started on 2021-05-27. Estimated completion is 2028-07-07.
What conditions does trial NCT04895709 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, Melanoma, Cervical Cancer, Urothelial Carcinoma, Pancreatic Adenocarcinoma.
What interventions are being tested in trial NCT04895709?
The interventions under investigation include: Docetaxel (DRUG), BMS-986340 (DRUG), BMS-936558-01 (DRUG).
Who is sponsoring clinical trial NCT04895709?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04895709 being conducted?
This trial has 20 study locations across California, Iowa, New Jersey, New York, Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04895709's enrollment target sits among peer trials
949 25th of 454 higher than 430 of 454 other Non-Small Cell Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-Small Cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
RECRUITING · Phase 1
-
Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC
RECRUITING · Phase 1
-
A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
RECRUITING · Phase 1
-
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
RECRUITING · Phase 1
-
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03784924 · 950 participants
EDRN Prostate MRI Biomarker Study
- NCT04180930 · 950 participants
An Evaluation of Two PTSD Assessments in an Active Duty and Military Veteran Sample
- NCT06087224 · 947 participants · NA
The TELENEO Trial: A Multicenter Trial of Telemedicine for Advanced Neonatal Resuscitations in Community Hospitals
- NCT04375033 · 952 participants · Phase 4
A Study Comparing Oral Buprenorphine and Injectable Buprenorphine for the Treatment of Opioid Use Disorder
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI